Glomerulonephritis (GN) is a group of rare diseases (<5 per 250,000 population), yet it is a leading cause of kidney failure and accounts annually for close to 20% of new cases of kidney failure/end stage kidney disease in Canada. Preventing progression to kidney failure is possible; however, there are several barriers and gaps in knowledge that need to be addressed to provide patients with individualized effective therapy.
As part of the SPOR Canadian GN Registry (CGNR) and Translational Research Initiative, we are collaborating with other centers across Canada to address these challenges. We are creating a registry by enrolling a large group of patients across the country with these types of glomerulonephritis: MCD (minimal change disease), FSGS (Focal and segmental glomerulosclerosis), MN (Membranous nephropathy), Mesangioproliferative Glomerulonephritis (MPGN) or IgAN (Immunoglobulin A nephropathy). Participation involves a hospital visit twice a year over a two-year period to collect medical information, demographics (such as age and gender), as well as blood and urine samples. These data will be an invaluable resource for translational research of this set of kidney diseases.
For more information, please visit the ClinicalTrials.gov webpage that outlines the study details here. For general inquires about this study, please email email@example.com.